Trial Profile
A phase I, open-label, parallel, single-center, randomized, cohort, placebo controlled, single-dose dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics pharmacokinetics of Cabotegravir (GSK1265744) in healthy HIV-seronegative volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacokinetics
- 30 Dec 2015 New trial record